Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Axonics Square Up To Medtronic In Sacral Neuromodulation Market?

This article was originally published in Clinica

Executive Summary

Signaling its entry into a small but fast-growing segment of the implantable neurostimulation market, Axonics Modulation Technologies has CE marked its sacral neuromodulation (SNM) system for treating overactive bladder (OAB), fecal incontinence and urinary retention. It is the first device of its kind to be rechargeable, significantly extending its longevity and giving Axonics what it believes to be a clinical and economic advantage over rivals such as medtech heavyweight Medtronic, which has been in this market since the late 1990s with its Interstim system.